Huons BioPharma signs $83.4M Hutox supply deal with Haemato Pharm

Huons BioPharma signed a deal potentially worth 97.2 billion won ($83.4 million) with Germany's Haemato Pharm to supply its Hutox botulinum toxin for sale in 29 European countries. The deal includes clinical trials in Europe, with marketing expected to begin in 2025.

“With the supply deal with Haemato, Huons is set to enter the world’s three largest botulinum toxin markets, the United States, China and Europe.”koreajoongangdaily.com

• 1 source
• koreajoongangdaily.comHuons BioPharma signs big Hutox deal with Germany's Haemato PharmSARAH CHEAOct 26, 2021

Summarized from public sources; check the original articles before acting on it.